IPR Blog covers the latest developments in inter partes review (IPR) proceedings under the America Invents Act (AIA).
Articles: 1-10 of 14
Chance at a second bite: no estoppel as to redundant ground
USA - September 21 2015 It has been close to three years since the PTAB first exercised its discretion to decline institution of inter partes review grounds it found to be…
PTAB ruling breaks ranks with Supreme Court and Federal Circuit
USA - August 27 2015 In a recent trial institution decision, the Patent Trial and Appeal Board held that a business method patent for trading securities was patent…
Big pharma prevails against hedge fund, but it’s no silver bullet
USA - August 25 2015 Yesterday, the PTAB issued its first two decisions addressing inter partes review petitions filed by Kyle Bass and his hedge fund Hayman Capital. In…
USPTO publishes proposed amendments to the rules of practice for trials before the Patent Trial and Appeal Board
USA - August 19 2015 Today, the USPTO published proposed amendments to the rules of practice for trials before the Patent Trial and Appeal Board (PTAB). The USPTO, in…
Division at the PTAB: split panel denies joinder “as a party” to a proceeding in which it is already a party
USA - July 24 2015 The PTAB continues to be split on the question of whether the PTAB has the authority to join an otherwise time-barred party to a inter partes review…
Big pharma fires defensive missile: complaint filed for attempted extortion
USA - June 24 2015 Big pharma continues to be on the defensive against IPR attacks by financiers, this time, by filing a civil law suit against a financier/IPR…
Sanctioning the “spider”: big pharma fights back against Kyle Bass’ IPR campaigns
USA - June 15 2015 Kyle Bass and his hedge fund Hayman Capital have become infamous for challenging the validity of patents owned by large biopharmaceutical companies…
PTAB issues second ruling on scope of estoppel after final decision
USA - June 1 2015 In its second ruling on the scope of estoppel, the Board has rejected a patent owner's attempt to terminate an AIA trial based on a final written…
Financier’s short-and-petition strategy targets more drugs: nine and counting
USA - April 29 2015 We recently referenced Coalition for Affordable Drugs LLC's ("CFAD") unconventional practice of filing inter partes review petitions seeking to…
PTAB rules on scope of estoppel following final decision
USA - April 24 2015 In its first ruling on the scope of estoppel under 35 U.S.C. §315(e)(1) following a final IPR decision, the Board has denied institution of…
About IPR Blog
Featured authors
